Our defiant goal is to reverse the cancer mortality trend. We’re doing this through a comprehensive pipeline that addresses the hallmarks of cancer. With an emphasis on immuno-oncology and antibody drug conjugates (ADCs), we are unleashing the power of our own immune systems and targeting tumors with lethal drugs.
Profoundly potent, cell specific and with a long-lasting memory, immuno-oncology has the potential to transform cancer care. Our robust cancer immunotherapy portfolio scrutinizes every escape mechanism, and we're designing novel drugs that address PD-1/PD-L1, CTLA4, OX40, and GITR pathways.
Antibody Drug Conjugates ADCs
ADCs are among the most powerful technologies for the treatment of cancer. We’re building on this phenomenon, developing novel ADC targets that include therapy-resistant tumors and cancer stem cells. We also have two best-in-class payloads, and we’re using our antibody engineering expertise for site-specific conjugation and next-generation ADCs.
Our comprehensive portfolio supports combination therapies, and we’re identifying these strategically through proof-of-concept studies. In addition to looking at “brakes-on, gas-off” approaches that block PD-1 and allow antigen release, our investigations are revealing other possible immunotherapy combinations.
Getting to answers quickly often means sorting through hundreds of phenotypes. Tissue phenomics allows us to mine these data faster and more precisely. This helps us to discover, develop and validate new biomarkers, design better clinical trials, and improve patient stratification and decision making.
Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase
Effect of the siliconization method on particle generation in a monoclonal antibody formulation in pre-filled syringes
Join us at MedImmune
Our Great Place to Work strategic initiative offers a dynamic environment that fosters collaboration and innovation. We attract top minds, and we do what it takes to nurture and build talent.